Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study

(2017) Narendranath Epperla et al.   HEMATOLOGICAL ONCOLOGY

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

(2017) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

(2017) Tjeerd Barf et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

(2016) Caron Jacobson et al.   BLOOD

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

(2016) Beiying Dai et al.   BLOOD

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

(2016) D. Chiron et al.   BLOOD

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma

(2016) Nakhle S. Saba et al.   BLOOD

Postibrutinib outcomes in patients with mantle cell lymphoma

(2016) P. Martin et al.   BLOOD

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Second-generation inhibitors of Bruton tyrosine kinase

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

(2016) Michael L Wang et al.   LANCET ONCOLOGY

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant

(2016) A Hamasy et al.   LEUKEMIA

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

(2016) Y Li et al.   ONCOGENE

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

(2016) Atish Mohanty et al.   Oncotarget

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

(2015) C. Y. Cheah et al.   ANNALS OF ONCOLOGY

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

(2015) H. S. Walter et al.   BLOOD

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

(2015) M. F. M. de Rooij et al.   BLOOD

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

(2015) Q. Yang et al.   CLINICAL CANCER RESEARCH

Novel ALK inhibitors in clinical use and development

(2015) Chaitanya Iragavarapu et al.   Journal of Hematology & Oncology

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

(2015) Shundong Cang et al.   Journal of Hematology & Oncology

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

(2015) David Chiron et al.   Oncotarget

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells

(2014) Jiao Ma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

(2014) M Spaargaren et al.   ONCOGENE

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

(2014) D. Chiron et al.   Cancer Discovery

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma

(2013) M Axelrod et al.   LEUKEMIA

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

(2013) Munevver Cinar et al.   LEUKEMIA RESEARCH

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

(2012) L. Zhang et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

(2012) L. P. Kil et al.   BLOOD

Toll-like receptor-4 signaling in mantle cell lymphoma

(2012) Lijuan Wang et al.   CANCER

Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor  B pathways

(2012) D. J. Medina et al.   HAEMATOLOGICA

3’UTR mediated regulation of the cyclin D1 proto-oncogene

(2011) Anagha Deshpande et al.   CELL CYCLE

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents

(2011) Cyrille Touzeau et al.   CLINICAL CANCER RESEARCH

T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1

(2011) Jens Staal et al.   EMBO JOURNAL

NF-κB Induction of the SUMO Protease SENP2: A Negative Feedback Loop to Attenuate Cell Survival Response to Genotoxic Stress

(2011) Moon Hee Lee et al.   MOLECULAR CELL

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

(2011) Xingguang Liu et al.   NATURE IMMUNOLOGY

The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies

(2011) Jan A. Burger et al.   SEMINARS IN CANCER BIOLOGY

The Src, Syk, and Tec family kinases: Distinct types of molecular switches

(2010) J. Michael Bradshaw   CELLULAR SIGNALLING

Mantle cell lymphoma: state-of-the-art management and future perspective

(2010) Oliver Weigert et al.   LEUKEMIA & LYMPHOMA

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

(2009) Antonina V. Kurtova et al.   BLOOD

Augmented TLR9-induced Btk activation in PIR-B–deficient B-1 cells provokes excessive autoantibody production and autoimmunity

(2009) Tomohiro Kubo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

(2008) Yuhong Zhou et al.   CANCER

Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen

(2008) Michele Weber et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE